Evidence map›Paper›PMID 20020123›Full record

ArticleCancer immunology, immunotherapy : CII2010

Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells.

Zoran Popmihajlov, Fabio R Santori, Daniel Gebreselassie, Anthony D Sandler, Stanislav Vukmanovic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zoran PopmihajlovMichael Heidelberger Division of Immunology, Department of Pathology and NYU Cancer Center, NYU School of Medicine, New York, NY 10016, USA.
Fabio R Santori
Daniel Gebreselassie
Anthony D Sandler
Stanislav Vukmanovic

Funding

RECEPTOR/LIGAND INTERACTIONS IN T CELL DIFFERENTIATIONR01AI041573 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI VUKMANOVIC, STANISLAV · 1998 to 2007
$1.7M
DYNAMICS OF PERIPHERAL T CELL REPERTOIRER01AI048837 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI VUKMANOVIC, STANISLAV · 2002 to 2006
$1.7M
NIAID NIH HHS AI41573NIAID NIH HHS AI48837NIAID NIH HHS R01 AI041573NIAID NIH HHS R01 AI048837
6 · The paper itself

Abstract

High avidity for antigen and diversity of T cell receptor (TCR) repertoire are essential for effective immunity against cancer. We have previously created a transgenic mouse strain with increased TCR avidity in a diverse T cell population. In this report, we show that strong alloreactive responses of transgenic T cells against targets with low MHC class I expression can be used for effective adoptive transfer of tumor immunity in vivo. Alloreactive transgenic T cells could be an effective therapeutic approach counteracting tumor evasion of the immune system.

Indexed as

AnimalsATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 2beta 2-MicroglobulinCD8-Positive T-LymphocytesH-2 AntigensHistocompatibility Antigen H-2DLymphomaMajor Histocompatibility ComplexMiceMice, TransgenicReceptors, Antigen, T-CellSurvival RateT-Lymphocytes, CytotoxicATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 2beta 2-MicroglobulinH-2 AntigensHistocompatibility Antigen H-2DReceptors, Antigen, T-CellTap1 protein, mouse

Identifiers

PMID20020123
PMCPMC11030666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.